ST Huicheng announced that Ruien Pharmaceutical, the holding subsidiary of the company, transferred the rights of orlistat capsule drug registration approval, drug marketing license holders and related technical data and intellectual property rights held by Startron Pharma for 7.027,800 yuan. Recently, Ruian Pharmaceutical received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration. The drug's marketing license holder has changed to Ruien Pharmaceutical. The drug approval number has not changed, there are no changes in production sites, prescriptions, etc., and can be marketed and sold after passing GMP compliance checks and meeting release requirements. There is uncertainty about the impact of this matter on the company's future performance.

ST Huicheng announced that Ruien Pharmaceutical, the holding subsidiary of the company, transferred the rights of orlistat capsule drug registration approval, drug marketing license holders and related technical data and intellectual property rights held by Startron Pharma for 7.027,800 yuan. Recently, Ruian Pharmaceutical received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration. The drug's marketing license holder has changed to Ruien Pharmaceutical. The drug approval number has not changed, there are no changes in production sites, prescriptions, etc., and can be marketed and sold after passing GMP compliance checks and meeting release requirements. There is uncertainty about the impact of this matter on the company's future performance.